In the control group , four patients ( 36 % ) developed no-reflow compared to none in the adenosine-treated patient ; P < 0.05 CONCLUSIONS : This study provides the first evidence that high-dose intragraft adenosine infusion compared with placebo protects microvascular function and prevents no-reflow during SVGs intervention .